Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
This study is to evaluate available local data in Iraqi patients with moderate to severe
 psoriasis on Enbrel treatment with regards to efficacy, treatment regimen adherence and
 patient characterization (i.e. age, gender, smoking status) using data from the
 Dermatologists in Baghdad Teaching Hospital registry
Inclusion Criteria:

 -  Confirmed diagnosis of moderate to severe plaque psoriasis receiving etanercept
 treatment for a minimum duration of 1 year.

 -  Age ≥18 years old.

 -  No history of using a biological treatment, other than etanercept, for treatment of
 moderate to severe plaque psoriasis or any other reason.

 Exclusion Criteria:

 -  Etanercept use for treatment moderate to severe plaque psoriasis less than 1 year
 duration.

 -  Previous use of other biological treatments for any reason